[The efficacy of antioxidant treatment with mexidol forte in 250 patients with chronic cerebral venous insufficiency]. / Klinicheskaya effektivnost' antioksidantnoi terapii Meksidolom FORTE 250 patsientov s khronicheskoi tserebral'noi venoznoi nedostatochnost'yu.

OBJECTIVE: To study the efficacy and safety of complex treatment with 2-ethyl-3-hydroxy-6-methylpyridine (mexidol forte 250) and venotonic drugs L-lysine aescinat and diosmin/hesperidin in patients with chronic cerebral venous insufficiency (CCVI). MATERIAL AND METHODS: One hundred and twenty CCVI patients with clinical and ultrasonic signs of cerebral venous discirculation were studied. Patients were stratified into group 1 (n=40) treated perorally with mexidol forte 250 and diosmin/hesperidin during 74 days in combination with two courses of L-lysine aescinat intravenously on the 1st and 30th days from baseline, group 2 (n=40) treated with mexidol forte 250 and diosmin/hesperidin during 74 days, group 3 (n=40) treated perorally with diosmin/hesperidin during 74 days. RESULTS AND CONCLUSION: The efficacy and safety of the complex treatment of CCVI patients with venotonic drugs with the inclusion of mexidol forte 250 at a dose of 750 mg/day for 74 days is shown. The study demonstrates a significant positive effect of mexidol forte 250 on the dynamics of complaints and indicators of the neurological and psychoemotional status of patients. Monotherapy with the venotonic drug diosmin/hesperidin shows its insufficient efficacy.

[Treatment of chronic cerebral venous insufficiency: a study on an effect of L-lysine aescinat]. / Lechenie khronicheskoi tserebral'noi venoznoi nedostatochnosti: izuchenie vliyaniya L-lizina estsinata.

AIM: To study an effect of L-lysine aescinat on the dynamics of complaints, severity of neurological syndromes and parameters of cerebral blood flow estimated by transcranial doppler and duplex scanning in patients with chronic cerebral venous insufficiency (CCVI). MATERIAL AND METHODS: Eighty patients with ultrasound-confirmed CCVI were examined. The basic group included 40 patients who received two treatment courses (intravenous drop-by-drop/stream introductions of L-lysine aescinat in the dose of 5ml during 7 days in 2nd and 30th days of examination). The comparison group consisted of 40 patients. RESULTS AND CONCLUSION: Treatment with L-lysine aescinat led to the significant decrease in complaints and improved the scores on the scales used in the study. There was an improvement in the cerebral hemodynamics (an increase of hemodynamic reserve and normalization of the linear blood flow velocity in deep veins) in the patients with CCVI. The safe profile of L-lysine aescinat used in recommended doses was confirmed.

[The epidemiological features of concomitance of diabetes mellitus and pulmonary tuberculosis].

The study was undertaken to reveal the clinical and epidemiological features of development diabetes mellitus (DM) and pulmonary tuberculosis (PT) in comorbidity. The material of the study was 143 case histories and outpatient cards of patients with DM and PT who were registered in 2001-2006. A total of 11,702 cases of tuberculosis were notified in 1999-2005. The significance ofa difference between the extensive indices was assessed by Student's test preceded by the Fisher angular transformation. Thus, the specific features of development of DM and PT are: 1) type 1 DM frequently occurs in youth while type 2 DM does at mature age; 2) tuberculosis in DM patients occurs at mature and old ages; 3) there is a male preponderance among patients with type 1 DM and a female predominance among those with type 2 DM; 4) comorbidity is more common in town-dwellers; 5) severe PT was prevalent in type 1 DM; mild PT is rarely observed in type 2 DM; 6) in comorbidity, fibro-cavernous, cirrhotic tuberculosis, caseous pneumonia, and tuberculoma are encountered by several times more frequently and focal tuberculosis and tuberculous pleurisy are less frequently in patients without DM.